Biological properties of interleukin 2 and its role in pathogenesis of selected diseases - A review

Medical Science Monitor

Volumn 14, Issue 10, 2008, Pages

  Olejniczak, Karolina ^a   Kasprzak, Aldona ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Interleukin 2; Interleukin 2 receptor; Pathogenesis

Indexed keywords

DACLIZUMAB; DENILEUKIN DIFTITOX; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; RECOMBINANT INTERLEUKIN 2; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LEUKEMIA; APATHY; BIOLOGICAL ACTIVITY; BLOOD PRESSURE; DRUG HALF LIFE; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; KIDNEY FAILURE; LOW DRUG DOSE; LYMPHOMA; MELANOMA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DEFECT; SOLID TUMOR;

HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-2; NEOPLASMS; PROTEIN SUBUNITS; RECEPTORS, INTERLEUKIN-2; SIGNAL TRANSDUCTION;

EID: 54249170206     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Morgan DA, Ruscetti F, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrow. Science, 1976; 193: 1007-8
2. Smith KA: Interleukin-2: inception, impact, and implications. Science, 1988; 240: 1169-76
3. Bazan JF: Unraveling the structure of IL-2. Science, 1992; 257: 410-13
4. Taniguchi T, Matsui H, Fujita T et al: Structure and expression of a cloned cDNA for human interleukin-2. Nature, 1983; 302: 305-10
5. Fujita T, Takaoka C, Matsui H, Taniguchi T: Structure of the human interleukin 2 gene. Proc Natl Acad Sci USA, 1983; 80: 7437-41
6. Seigel LJ, Harper ME, Wong-Staal F et al: Gene for T-cell growth factor: location on human chromosome 4q and feline chromosome B1. Science, 1984; 223: 175-78
7. Rosenberg SA, Grimm EA, McGrogan M et al: Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science, 1984; 223: 1412-14
8. Nakanishi K, Hirose S, Yoshimoto T: Role and regulation of interleukin (IL)-2 receptor α and β chains in IL-2- driven B-cell growth. Proc Natl Acad Sci USA, 1992; 89: 3551-55
9. Minami Y, Kono T, Miyazaki T, Taniguchi T: The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol, 1993; 11: 245-67
10. Gesbert F, Delespine-Carmagnat M, Bertoglio J: Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol, 1998; 18: 307-20
11. Rubin LA, Kurman CC, Fritz ME et al: Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol, 1985; 135: 3172-77
12. Robb RJ, Kutny RM: Structure-function relationships for the IL-2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol, 1987; 139: 855-62
13. Gutgsell NS, Malek TR: Formation of high affinity IL-2 receptors is dependent on a nonligand binding region of the a subunit. J Immunol, 1994; 153: 3899-907
14. c on another cell to augment IL-2 signaling. J Immunol, 1998; 161: 5430-37
15. Waldmann TA: The interleukin-2 receptor. J Biol Chem, 1991; 266: 2681-84
16. Cosman D, Cerretti DP, Larsen A et al: Cloning, sequence and expression of human interleukin-2 receptor. Nature, 1984; 312: 768-71
17. Nikaido T, Shimizu A, Ishida N et al: Molecular cloning of a cDNA encoding human interleukin-2 receptor. Nature, 1984; 311: 631-35
18. Leonard WJ, Donlon TA, Lebo RV, Greene WC: Localization of the gene encoding the human interleukin-2 receptor on chromosome 10. Science, 1985; 228: 1547-49
19. Tsudo M, Kitamura F, Miyasaka M: Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. Proc Natl Acad Sci USA, 1989; 86: 1982-86
20. Hatakeyama M, Tsudo M, Minamoto S et al: Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science, 1989; 244: 551-56
21. Miyazaki T, Manuyama M, Yamada G et al: The integrity of the conserved 'WS motif' common to IL-2 and other cytokines receptors is essentials for ligand binding and signal transduction. EMBO J, 1991; 10: 3191-97
22. Gnarra JR, Otani H, Wang MG et al: Human interleukin 2 receptor beta-chain gene: Chromosomal localization and identification of 5-prime regulatory sequences. Proc Natl Acad Sci USA, 1990; 87: 3440-44
23. Shibuya H, Yoneyama M, Nakamura Y et al: The human interleukin-2 receptor beta-chain gene: Genomic organization, promotor analysis and chromosomal assignment. Nucleic Acids Res, 1990; 18: 3697-703
24. Noguchi M, Adelstein S, Cao X, Leonard WJ: Characterization of the human interleukin-2 receptor gamma chain gene. J Biol Chem, 1993; 268: 13601-8
25. Takeshita T, Asao H, Ohtani K et al: Cloning of the gamma chain of the human IL-2 receptor. Science, 1992; 257: 379-82
26. Noguchi M, Yi H, Rosenblatt HM et al: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell, 1993; 73: 147-57
27. Puck JM, Deschenes SM, Porter JC et al: The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet, 1993; 2: 1099-104
28. Russell SM, Keegan AD, Harada N et al: Interleukin-2 receptor gamma-chain: a functional component of the interleukin-4 receptor. Science, 1993; 262: 1880-83
29. Noguchi M, Nakamura Y, Russell SM et al: Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science, 1993; 262: 1877-80
30. Cosman D, Lyman SD, Idzerda RL et al: A new cytokine receptor superfamily. Trends Biochem Sci, 1990; 15: 265-70
31. Lin WC, Yasumura S, Suminami Y et al: Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol, 1995; 155: 4805-16
32. Wu Z, Johnson KW, Choi Y, Ciardelli TL: Ligand binding analysis of soluble Interleukin-2 Receptor complexes by surface plasmon resonance. J Biol Chem, 1995; 270: 16045-51
33. Liparoto SF, Myszka DG, Wu Z et al: Analysis of the role of the interleukin-2 receptor gamma chain in ligand binding. Biochemistry, 2002; 41: 2543-51
34. Rickert M, Boulanger M, Goriatcheva N, Garcia K: Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin 2 and its alpha, beta and gamma receptors. J Mol Biol, 2004; 339: 1115-28
35. Stauber D, Debler E, Horton P et al: Crystal structure of the interleukin-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA, 2006; 103: 2788-93
36. Smith KA: The structure of IL-2 bound to the three chains of the IL-2 receptor and how signaling occurs. Med Immunol, 2006; 5: 3
37. Martino A, Holmes JH, Lord JD et al: Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J Immunol, 2001; 166: 1723-29
38. Moon JJ, Rubio ED, Mertino A, Krumm A: A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem, 2004; 279: 5520-27
39. Cacalano NA, Johnston J: Interleukin-2 signaling and inherited immunodeficiency. Am J Hum Genet, 1999; 65: 287-93
40. Antony PA, Paulos CM, Ahmadzadeh M et al: Interleukin-2-dependent mechanism of tolerance and immunity in vivo. J Immunol, 2006; 176: 5255-66
41. Nelson BH: IL-2 regulatory T cells, and tolerance. J Immunol, 2004; 172: 3983-88
42. Cantrell DA, Smith KA: Transient expression of interleukin-2 receptors: consequences for T-cell growth. J Exp Med, 1983; 158: 1895-911
43. Gillis S, Conlon PJ, Cosman D et al: Lymphokines: from conjecture to the clinic. Seminars Oncol, 1986; 13: 218-27
44. Holda JH, Maier T, Claman HN: Natural suppressor activity in graft-vs-host spleen and normal bone marrow is augmented by IL-2 and interferon-γ. J Immunol, 1986; 137: 3538-43
45. Trinchieri G, Matsumoto-Kobayashi M, Clark SC et al: Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med, 1984; 160: 1147-69
46. Caligiuri MA, Zmuidzinas A, Manley TJ et al: Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: Identification of a novel killers cell subset with high affinity receptors. J Exp Med, 1990; 171: 1509-26
47. Phillips J, Lanier LL: Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocyte to lysis. J Exp Med, 1986; 164: 814-25
48. Voss SD, Sondel PM, Robb RJ: Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: Association of the p64 IL-2Rγ chain with the IL-2Rβ chain in functional intermediate-affinity IL-2R. J Exp Med, 1992; 176: 531-41
49. Jelinek DF, Splawski JB, Lipsky PE: The roles of interleukin 2 and interferon-γ in human B cell activation, growth and differentiation. Europ J Immunol, 1986; 16: 925-32
50. Pike BL, Raubitschek A, Nossal GJV: Human interleukin 2 can promote the growth and differentiation of single hapten-specific B cells in the presence of specific antigen. Proc Natl Acad Sci USA, 1984; 81: 7917-21
51. Muraguchi A, Kehrl JH, Longo DL et al: Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med, 1985; 161: 181-97
52. Civallero M, Barni S, Nano R, Capelli E: Dendritic cells and interleukin-2: cytochemical and ultrastructural study. Histol Histopathol, 2000; 15: 1077-85
53. Benveniste EN, Merrill JE: Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature, 1986; 321: 610-13
54. Reichert TE, Watkins S, Stanson J et al: Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem, 1998; 46: 603-11
55. Tigges MA, Casey LS, Koshland ME: Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway. Science, 1989; 243: 781-86
56. Smith KA: Lowest dose interleukin-2 immunotherapy. Blood, 1993; 81: 1414-23
57. Whittington R, Faulds D: Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs, 1993; 46: 446-514
58. Weineberg K, Parkman R: Severe combined immunodeficiency due to a specific defect in the production of interleukin-2. N Engl J Med, 1990; 322: 1718-23
59. Miyasaka N, Nakamura T, Russell IJ, Talar N: Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol, 1984; 31: 109-17
60. Tchórzewski H, Rotsztejn H, Banasik M et al: The involvement of immunoregulatory T cells in the pathogenesis of lichen sclerosus. Med Sci Monit, 2005; 11(1): CR39-43
61. Kirkpatrick CH, Davis KC, Horsburgh CR Jr et al: Interleukin-2 production by persons with the generalized lymphadenopathy syndrome or the acquired immune deficiency syndrome. J Clin Immunol, 1985; 5: 31-37
62. Foa R, Giovarelli M, Jamma J et al: Interleukin 2 and interferon gamma production by lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL-2 is absorbed by the neoplastic B cell population. Blood, 1985; 66: 614-19
63. Fisher JR, Schindel M, Bulzebruck H et al: Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer. Ann Oncol, 1997; 8: 457-61
64. Smith JB, Talal N: Significance of self-recognition and interleukin-2 for immunoregulation, autoimmunity and cancer. Scand J Immunol, 1982; 16: 269-78
65. Teodorczyk-Injeyan J, Sparkes BG, Mills GB et al: Impaired expression of interleukin 2 receptor (IL-2R) in the immunosupressed burned patient: reversal by exogenous IL-2. J Trauma, 1987; 27: 180-87
66. Kadhim H, Tabarki B, DePrez C et al: Interleukin-2 in the pathogenesis of perinatal white matter damage. Neurology, 2002; 58: 1125-28
67. Mallmann P, Mallmann R, Krebs D: Determination of tumor necrosis factor alpha (TNF alpha) and interleukin 2 (IL 2) in women with idiopathic recurrent miscarriage. Arch Gynecol Obstet, 1991; 249: 73-78
68. Komp DM, Shapiro E, McNamara J: Soluble interleukin-2 receptor in childchood non-Hodgkin's lymphoma. Blood, 1988; 71: 1172-74
69. Kuhn DJ, Ping Dou Q: The role of interleukin-2 receptor alpha in cancer. Front Biosci, 2005; 10: 1462-74
70. Bien E, Balcerska A: Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 2007; 28: 1-26
71. Hsu SM, Waldron JW, Hsu PL, Hough AJ: Cytokines in malignant lymphomas. Hum Pathol, 1993; 24: 1040-57
72. Kobayashi S, Imamura M, Hashino S et al: Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-a levels after allogenic bone marrow transplantation. Leukemia and Lymphoma, 1999; 33: 559-66
73. Ikeguchi M, Hirooka Y: Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie, 2005; 28: 255-59
74. Qiu FB, Wu LQ, Lu Y et al: Predominant expression of Th1-type cytokines in primary hepatic cancer and adjacent liver tissues. Hepatobiliary Pancreat Dis Int, 2007; 6: 63-66
75. Kuhn DJ, Smith DM, Pross S et al: Overexpression of interleukin-2 receptor in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem, 2003; 89: 824-36
76. Horiuchi S, Koyanagi Y, Yanaka Y et al: Altered interleukin-2 receptor α-chain is expressed in human T-cell leukaemia virus-type-I-infected T cell lines and human peripheral blood mononuclear cells of adult T-leukemiae patients through an alternative spicing mechanism. Immunology, 1997; 91: 28-34
77. Sheibani K, Winberg CD, Velde van de S et al: Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. Ann J Pathol, 1987; 127: 27-37
78. Tsilivacos V, Tsapis A, Kakolyris S et al: Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. Leukemia, 1994; 8: 1571-78
79. Peuchmaur M, Emilie D, Crevon C et al: IL-2 mRNA expression in Tac-positive malignant lymphomas. Am J Pathol, 1990; 136: 383-90
80. Strauchen JA, Breakstone BA: IL-2 receptor expression in human lymphoid lesions, immunohistochemical study of 166 cases. Am J Pathol, 1986; 126: 506-12
81. Rubin LA, Nelson DL: The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med, 1990; 113: 619-27
82. Aydin F, Yilmaz M, Ozdemir F et al: Correlation of serum IL-2, IL-6, and IL-10 levels with IPI in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol, 2002; 25: 570-72
83. Ozdemir F, Aydin F, Yilmaz M et al: The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive non-Hodgkin's lymphoma (NHL). J Exp Clin Cancer Res, 2004; 23: 485-88
84. Spachacz R, Kasprzak A, Stefańska K et al: Tissue expression of cytokines (IL-1α, IL-2, IL-6, IL-12, TNF-α) in B-cell lymphomas in children. Folia Morphol, 2003; 62: 483-85
85. De Vita F, Turitto G, di Grazia M et al: Analysis of interleukin-2/ interleukin-2 receptor system in advanced non-small cell lung cancer. Tumori, 1998; 84: 33-38
86. Naumnik W, Chyczewska E: The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer. Folia Histochem Cytobiol, 2001; 39: 185-86
87. Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M: Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol, 2007; 66: 159-66
88. Jothy S, Abadie A, Froussard P et al: Nuclear location of the p55 subunit of the IL-2 receptor following activation of the HT-2 T helper cell line. Ann Inst Pasteur Immunol, 1988; 139: 237-44
89. Kasprzak A, Seidel J, Adamek A et al: Interleukin 2 (IL-2) expression in liver of patients with chronic hepatitis C virus (HCV) infection. Folia Histochem Cytobiol, 2006; 44: 103-10
90. Kono N, Kanda Y, Yamamoto R et al: Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan. Leukemia and Lymphoma, 2000; 37: 151-56
91. Niitsu N, Iijima K, Chizuka A: A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol, 2001; 66: 24-30
92. Goto H, Tsurumi H, Takemura M et al: Serum soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol, 2005; 131: 73-79
93. Dmoszyńska A, Kandefer-Szerszeń M, Roliński J et al: Influence of low dose rIL-2 treatment on endogenous cytokines production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease. Leukemia and Lymphoma, 1999; 35: 355-66
94. Stasi R, Zinzani L, Galieni P et al: Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol, 1994; 88: 770-77
95. El Houda Agueznay N, Badoual C et al: Soluble inteleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationship. Clin Exp Immunol, 2007; 150: 114-23
96. Probst M, Buer J, Ganser A, Atzpodien S: Interleukin-2 in hematology and oncology: state of the art. Cancer J, 2003; 8: 5-19
97. Mitsuyasu RT: The potential role of interleukin-2 in HIV. AIDS, 2001; Suppl 2: 22-27
98. Rosenberg SA, Packard BS, Aebersold PM et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med, 1988; 319: 1676-80
99. Fiszer-Maliszewska L, Den Otter W, Mordarski M: Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength. Cancer Immunol Immunother, 1999; 47: 307-14
100. Vlk V, Eckschlager T, Kavan P et al: Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients. Pediatr Hematol Oncol, 2000; 17: 31-44
101. Masztalerz A, Everse LA, Otter WD: Presence of cytotoxic B220+CD3+CD4-CD8- cells correlates with the therapeutic efficacy of lymphoma treatment with IL-2 and/or IL-12. J Immunother, 2004; 27: 107-15
102. Boyman O, Surh CD, Sprent J: Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther, 2006; 6: 1323-31
103. Acres B, Gantzer M, Remy C et al: Fusokine Interleukin-2/Interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity. Cancer Res, 2005; 65: 9536-46
104. Waldmann TA, White JD, Goldman CK et al: The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood, 1993: 82: 1701-12